Cargando…
Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the global coronavirus disease 2019 (COVID-19) pandemic, and the search for effective treatments has been limited. Furthermore, the rapid mutations of SARS-CoV-2 have posed challenges to existing vaccines and neu...
Autores principales: | Yang, Zhe, Zhang, Qi, Wu, Xiaoqing, Hao, Siyuan, Hao, Xinbao, Jones, Elizabeth, Zhang, Yuxia, Qiu, Jianming, Xu, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377517/ https://www.ncbi.nlm.nih.gov/pubmed/37509657 http://dx.doi.org/10.3390/biomedicines11072019 |
Ejemplares similares
-
Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147
por: Yang, Zhe, et al.
Publicado: (2023) -
Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling
por: Zhang, Qi, et al.
Publicado: (2023) -
SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2
por: Fenizia, Claudio, et al.
Publicado: (2021) -
Repurposing niclosamide for the treatment of neurological disorders
por: Apolloni, Savina, et al.
Publicado: (2023) -
Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori
por: Tharmalingam, Nagendran, et al.
Publicado: (2018)